Open AccessHydroxychloroquine Treatment may Benefit Nucleic Acid Testing of SARS-CoV-2 Turning Negative in Critically ill COVID-19 Patients: Report of 3 Cases
Author(s) -
Chunyan Wei,
Yang Bai,
Zhiyao He,
Xiaofan Fei
Publication year - 2020
Publication title -
biointerface research in applied chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.216
H-Index - 11
ISSN - 2069-5837
DOI - 10.33263/briac111.76597664
Subject(s) - hydroxychloroquine , covid-19 , critically ill , medicine , coronavirus , outbreak , virology , intensive care medicine , disease , infectious disease (medical specialty)
Since the outbreak of coronavirus disease 2019(COVID-19), hundreds of thousands of people have been infected. After fighting with the virus for two months, the epidemic in China is well controlled. However, many countries are still struggling with the coronavirus. Effective anti-viral drugs are important to reverse the patient's condition, especially for critically ill patients. We report 3 cases of using hydroxychloroquine in the treatment of critically ill COVID-19 patients. Results show that hydroxychloroquine treatment may benefit nucleic acid testing, turning negative in these patients.